Hit 'em Where It Hurts: Gram-Negative Bacterial Lipopolysaccharide As a Vaccine Target

Overview

Journal Microbiol Mol Biol Rev

Publisher American Society for Microbiology

Specialty Microbiology

Date 2023 Jul 11

PMID 37432116

Authors

Alan S Cross

Affiliations

Soon will be listed here.

Abstract

Infections with antimicrobial-resistant (AMR) bacteria pose an increasing threat to the ability to perform surgical procedures, organ transplantation, and treat cancer among many other medical conditions. There are few new antimicrobials in the development pipeline. Vaccines against AMR Gram-negative bacteria may reduce the use of antimicrobials and prevent bacterial transmission. This review traces the origins of lipopolysaccharide (LPS)-based vaccines against Gram-negative bacteria, the role of O polysaccharides and LPS core regions as potential vaccine targets, the development of new vaccine technologies, and their application to vaccines in current development.

Citing Articles

Phage-resistance alters Lipid A reactogenicity: a new strategy for LPS-based conjugate vaccines against Rissen.

Cuomo P, Medaglia C, Casillo A, Gentile A, Fruggiero C, Corsaro M Front Immunol. 2024; 15:1450600.

PMID: 39723217 PMC: 11668645. DOI: 10.3389/fimmu.2024.1450600.

Lipopolysaccharide as a Vaccine Target and the Role of Antibodies in Protection from Disease.

Miller J, Cross A, Tennant S, Baliban S Vaccines (Basel). 2024; 12(10).

PMID: 39460343 PMC: 11512408. DOI: 10.3390/vaccines12101177.

Compartmentalization of the inflammatory response during bacterial sepsis and severe COVID-19.

Cavaillon J, Chousterman B, Skirecki T J Intensive Med. 2024; 4(3):326-340.

PMID: 39035623 PMC: 11258514. DOI: 10.1016/j.jointm.2024.01.001.

References

Fisher M . Development of immunotherapy for infections due to Pseudomonas aeruginosa. J Infect Dis. 1974; 130 Suppl(0):S149-51. DOI: 10.1093/infdis/130.supplement.s149. View

Cohen T, Pelletier M, Cheng L, Pennini M, Bonnell J, Cvitkovic R . Anti-LPS antibodies protect against Klebsiella pneumoniae by empowering neutrophil-mediated clearance without neutralizing TLR4. JCI Insight. 2017; 2(9). PMC: 5414560. DOI: 10.1172/jci.insight.92774. View

BRAUDE A, Siemienski J, Williams D, SANFORD J . Overwhelming bacteremic shock produced by gram-negative bacilli; a report of four cases with one recovery. Med Bull (Ann Arbor). 1953; 19(2):23-42. View

Riddle M, Kaminski R, Williams C, Porter C, Baqar S, Kordis A . Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine. Vaccine. 2011; 29(40):7009-19. DOI: 10.1016/j.vaccine.2011.07.033. View

Ravenscroft N, Haeuptle M, Kowarik M, Fernandez F, Carranza P, Brunner A . Purification and characterization of a Shigella conjugate vaccine, produced by glycoengineering Escherichia coli. Glycobiology. 2015; 26(1):51-62. DOI: 10.1093/glycob/cwv077. View

Schuster O, Sears K, Ramachandran G, Fuche F, Curtis B, Tennant S . Immunogenicity and protective efficacy against C-C infection in mice immunized with a glycoconjugate of Newport Core-O polysaccharide linked to the homologous serovar FliC protein. Hum Vaccin Immunother. 2018; 15(6):1436-1444. PMC: 6663135. DOI: 10.1080/21645515.2018.1483808. View

Rai A, Mitchell A . Enterobacterial Common Antigen: Synthesis and Function of an Enigmatic Molecule. mBio. 2020; 11(4). PMC: 7439462. DOI: 10.1128/mBio.01914-20. View

Plested J, Harris S, Wright J, Coull P, Makepeace K, Gidney M . Highly conserved Neisseria meningitidis inner-core lipopolysaccharide epitope confers protection against experimental meningococcal bacteremia. J Infect Dis. 2003; 187(8):1223-34. DOI: 10.1086/368360. View

Kim Y, Watson D . Role of antibodies in reactions to gram-negative bacterial endotoxins. Ann N Y Acad Sci. 1966; 133(2):727-45. DOI: 10.1111/j.1749-6632.1966.tb52402.x. View

10.

Choi M, Tennant S, Simon R, Cross A . Progress towards the development of Klebsiella vaccines. Expert Rev Vaccines. 2019; 18(7):681-691. PMC: 6656602. DOI: 10.1080/14760584.2019.1635460. View

11.

Rietschel E, Cavaillon J . Endotoxin and anti-endotoxin. The contribution of the schools of Koch and Pasteur: life, milestone-experiments and concepts of Richard Pfeiffer (Berlin) and Alexandre Besredka (Paris). J Endotoxin Res. 2002; 8(2):71-82. DOI: 10.1179/096805102125000218. View

12.

ROGERS D . The changing pattern of life-threatening microbial disease. N Engl J Med. 1959; 261:677-83. DOI: 10.1056/NEJM195910012611401. View

13.

Bailat S, Heumann D, Le Roy D, Baumgartner J, Rietschel E, Glauser M . Similarities and disparities between core-specific and O-side-chain-specific antilipopolysaccharide monoclonal antibodies in models of endotoxemia and bacteremia in mice. Infect Immun. 1997; 65(2):811-4. PMC: 176131. DOI: 10.1128/iai.65.2.811-814.1997. View

14.

Young L, Meyer R, Armstrong D . Pseudomonas aeruginosa vaccine in cancer patients. Ann Intern Med. 1973; 79(4):518-27. DOI: 10.7326/0003-4819-79-4-518. View

15.

Neu H . The crisis in antibiotic resistance. Science. 1992; 257(5073):1064-73. DOI: 10.1126/science.257.5073.1064. View

16.

Martin P, Alaimo C . The Ongoing Journey of a Bioconjugate Vaccine. Vaccines (Basel). 2022; 10(2). PMC: 8878964. DOI: 10.3390/vaccines10020212. View

17.

Seeberger P, Pereira C, Khan N, Xiao G, Diago-Navarro E, Reppe K . A Semi-Synthetic Glycoconjugate Vaccine Candidate for Carbapenem-Resistant Klebsiella pneumoniae. Angew Chem Int Ed Engl. 2017; 56(45):13973-13978. PMC: 5819008. DOI: 10.1002/anie.201700964. View

18.

Ramirez Sevilla C, Gomez Lanza E, Llopis Manzanera J, Martin J, Sanz M . Active immunoprophyilaxis with uromune® decreases the recurrence of urinary tract infections at three and six months after treatment without relevant secondary effects. BMC Infect Dis. 2019; 19(1):901. PMC: 6819445. DOI: 10.1186/s12879-019-4541-y. View

19.

. The Genus Salmonella Lignières, 1900. J Hyg (Lond). 2010; 34(3):333-50. PMC: 2170865. DOI: 10.1017/s0022172400034677. View

20.

Ma C, McClean S . Mapping Global Prevalence of and Recent Vaccine Development to Tackle It. Vaccines (Basel). 2021; 9(6). PMC: 8226933. DOI: 10.3390/vaccines9060570. View